Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...

Dose Size and Dosing Frequency: Determination Methods

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Switching to alternative tobacco products during unsuccessful smoking quit attempts is not linked to improved quit intention or interest.

Addiction science & clinical practice·2026

Same author

Flavored nicotine pouch use in the United States: Mint represents the leading flavor.

Preventive medicine reports·2026

Same author

Emerging tobacco use patterns in the United States: Tobacco use behaviors associated with current use of nicotine pouches.

PloS one·2026

Same author

Current Use of Cigarettes in the United States: The Joint Role of Race/Ethnicity and Health Insurance Coverage.

Healthcare (Basel, Switzerland)·2023

Same author

Negative impact of chronic pandemic-specific financial stress on food security among college students.

Journal of American college health : J of ACH·2023

Same author

Correlates of COVID-19 vaccine uptake among U.S. College students.

Preventive medicine reports·2023

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

On Identifying Minimum Efficacious Doses in Combination Drug Trials.

Julia N Soulakova¹, Allan R Sampson

¹Department of Statistics, University of Nebraska-Lincoln, 340 Hardin Hall-North, Lincoln, NE 68583-0963 (E-mail: jsoulakova2@unlnotes.unl.edu ).

Statistics in Biopharmaceutical Research

|August 14, 2009

Summary

This summary is machine-generated.

This study introduces a method to identify minimum efficacious dose sets for combination drugs, ensuring regulatory approval by demonstrating superior efficacy and component contribution. The procedure controls error rates and estimates the optimal combination dose.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Related Experiment Videos

Last Updated: Jun 21, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Area of Science:

Pharmacology
Biostatistics
Drug Development

Background:

Regulatory agencies like the FDA require rigorous proof of efficacy for combination drugs.
Demonstrating a combination drug's effectiveness necessitates showing the combination's superiority and each component's contribution.

Purpose of the Study:

To develop a statistical procedure for identifying minimum efficacious dose sets in combination drug studies.
To ensure that the identified combination is the lowest dose demonstrating efficacy, meeting regulatory standards.

Main Methods:

Utilizing a closed testing principle with a graph-based approach to establish hypothesis testing order.
Employing an "average" test to evaluate hypotheses related to minimum efficacious dose sets.
Identifying all potential minimum efficacious dose sets and their corresponding hypotheses for a given study design.

Main Results:

The proposed procedure demonstrates strong control of the overall error rate.
Simulation studies were conducted to evaluate the power of the developed statistical procedure.
The method effectively identifies combinations where the overall drug effect is superior to individual components.

Conclusions:

The developed statistical procedure provides a robust framework for identifying minimum efficacious dose sets for combination drugs.
This approach aids in meeting FDA requirements for demonstrating both combination efficacy and individual component contribution.
The method is crucial for optimizing drug dosages and ensuring therapeutic effectiveness in clinical development.